Draft — PhD/MPhil Pharmacology (2026 entry)

MOTIVATION LETTER

The CCT model began with a clinical observation from my years as a pharmacist: patients relapse not because they forget the drug experience, but because they cannot stop remembering it. Reward-memory encoding sits at the intersection of pharmacology and neuroscience, yet most addiction research treats these as separate domains. My work builds a quantitative bridge between them.

The Conjunctive Consolidation Threshold model is a tripartite pharmacological framework for reward-memory encoding prevention in addiction. It couples three axes, dopaminergic reward prediction error, NMDAR-dependent long-term potentiation, and affective contrast, into a single ODE system solved with RK45. I calibrated all 14 free parameters using Bayesian MCMC (PyMC DEMetropolisZ) against priors elicited from a systematic screen of 1,847 records. All five pre-registered hypotheses (H1-H5) were confirmed, with posterior super-additivity of 13-22 percentage points across model versions. Three sole-authored preprints are under review at peer-reviewed journals (IART, PNPBP, NBR), and a co-authored paper is under review at Alcohol (Elsevier).

The University of Manchester's PhD/MPhil Pharmacology programme is the right environment to take this from theoretical model to experimentally testable predictions. The Centre for Applied Pharmacokinetic Research has the PK/PD expertise to ground my circuit-level parameters in measured drug concentrations. The neuropharmacology groups have the wet-lab capacity to test the CCT model's predictions about which receptor combinations produce super-additive effects on memory consolidation. My computational framework generates specific, falsifiable predictions about dose ratios and timing windows; these need experimental collaborators to close the loop.

My academic record supports this trajectory. I hold a B.Pharm from the University of Ibadan (CGPA 5.1/7.0, German equivalent 1.9, Upper Second Division) and am currently enrolled in the M.Sc. Digital Health programme at Hasso Plattner Institute / University of Potsdam. I am a PCN-licensed pharmacist with clinical experience at Ramset Pharmacy and research experience in AMR genomics at GHRU-GSAR. I have endorsements from Kent Berridge (Michigan), Samuel Gershman (Harvard), Nathaniel Daw (Princeton), and Marcelo Mattar (NYU).

The CCT model addresses a real clinical problem: addiction relapse. It uses quantitative methods that match this programme's emphasis on drug mechanisms and signaling pathways. I am applying because Manchester has the combination of pharmacokinetic expertise and neuropharmacology infrastructure that my model needs to move from preprint to experiment.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold (CCT) model addresses a specific gap in addiction pharmacology: the field lacks a mechanistic, quantitative account of how pharmacological interventions can prevent the encoding of reward-associated memories during the consolidation window. Current treatments target either dopamine signaling or glutamate signaling in isolation. Clinical evidence suggests combination approaches work better, but no framework explains why.

The CCT model proposes that reward-memory encoding requires the conjunctive crossing of a threshold across three coupled systems: dopaminergic reward prediction error, NMDAR-dependent long-term potentiation, and affective contrast (the emotional salience differential between drug and non-drug states). The model is implemented as a system of coupled ODEs solved with RK45. The 14 free parameters were calibrated using Bayesian MCMC (PyMC DEMetropolisZ) with priors elicited from a systematic literature screen of 1,847 records covering receptor binding kinetics, synaptic plasticity time constants, and behavioral pharmacology data.

All five pre-registered hypotheses (H1-H5) were confirmed. The central finding is super-additivity: combined modulation across the three axes produces 13-22 percentage point greater reduction in predicted memory consolidation than the sum of individual-axis effects. This has direct therapeutic implications. It predicts specific dose ratios and timing windows for combination therapies that would not be discovered through single-target screening.

The model has been validated through three sole-authored preprints (OSF/Zenodo), each currently under review at a peer-reviewed journal (IART, PNPBP, NBR). A co-authored paper extending the framework is under review at Alcohol (Elsevier). The computational infrastructure, including all calibration code and data, is publicly available on GitHub.

The next phase requires experimental grounding. The CCT model makes specific predictions: (1) sub-threshold doses of a D2 antagonist combined with an NMDAR partial agonist should block reward-memory consolidation at doses where neither compound works alone; (2) the affective contrast axis predicts that environmental enrichment interventions shift the threshold, changing the required pharmacological dose; (3) the timing window for effective intervention is bounded by the LTP consolidation curve, predicting a critical period of approximately 6-12 hours post-exposure.

The University of Manchester's PhD/MPhil Pharmacology programme offers the resources to test these predictions. The Centre for Applied Pharmacokinetic Research can provide the PK/PD modeling expertise to translate my circuit-level parameters into dosing regimens. The neuropharmacology groups have established behavioral pharmacology infrastructure for addiction models. I am seeking a supervisor with expertise in either dopamine signaling or synaptic plasticity who is interested in computational-experimental collaboration.

My background supports this transition. I am a licensed pharmacist (PCN) with clinical experience, which grounds my modeling in real drug behavior. I have published computational work in drug resistance prediction (TOPOLOGIX, AUROC 0.804 on the Platinum benchmark) and have built a receptor-to-behavior simulation engine (neurocascade) with 62 passing tests. The CCT model is the most mature of my research lines, with pre-registered hypotheses, Bayesian calibration, and confirmed predictions. It is ready for experimental testing.

SHORT ANSWER ESSAY: RESEARCH EXPERIENCE

My research experience spans computational pharmacology, protein ML, and dynamical systems. The most relevant line for this programme is the CCT model, a tripartite framework for reward-memory encoding prevention in addiction. I designed the model architecture, implemented the ODE system (RK45), calibrated all 14 free parameters using Bayesian MCMC (PyMC DEMetropolisZ), and confirmed all five pre-registered hypotheses. The work is documented in three sole-authored preprints under review at IART, PNPBP, and NBR.

I have also conducted rigorous negative-result research. My cardiotoxicity topology study tested whether bipartite persistent homology predicts hERG cardiotoxicity from protein-ligand interface geometry. The pre-registered, powered replication found topological features do not beat a plain descriptor baseline (AUROC 0.8426 vs 0.8782). This settled a comparison the literature had never actually run. Similarly, my interface-topology-for-resistance study found topological constructs carry almost no signal for drug-resistance prediction (AUROC 0.425 and 0.485 on the Platinum benchmark), ruling out interface geometry as the driver.

These negative results inform my current work. TOPOLOGIX uses ESM-2 protein-language-model delta-embeddings plus Morgan/ECFP fingerprints with a Random Forest classifier, achieving AUROC 0.804 on the Platinum benchmark and 0.634 on SKEMPI 2.0, beating structure-based baselines while covering 100% of mutations versus approximately 18% for structure-limited tools.

I have also built neurocascade, a receptor-to-behavior brain-circuit simulation engine coupling pharmacokinetics to receptor binding to Wilson-Cowan circuit dynamics to behavioral readouts, with 62 passing tests. My ergofluids project extends Koopman-operator methods with a Mori-Zwanzig memory kernel for drug transport modeling; the first real-data gate did not meet its pre-registered criterion, and I reported that directly rather than reframing it.

SHORT ANSWER ESSAY: WHY THIS PROGRAMME

The University of Manchester's PhD/MPhil Pharmacology programme is the right fit for the CCT model because of three specific alignments. First, the Centre for Applied Pharmacokinetic Research has the PK/PD modeling expertise needed to translate my circuit-level parameters into experimentally testable dosing regimens. My model currently operates at the level of receptor binding and synaptic plasticity; it needs pharmacokinetic grounding to make concrete predictions about drug concentrations over time.

Second, the neuropharmacology groups at Manchester have established behavioral pharmacology infrastructure for addiction models. The CCT model generates specific predictions about dose ratios, timing windows, and environmental modulation of pharmacological thresholds. These predictions require experimental testing in animal models, which Manchester can provide.

Third, the programme's emphasis on drug mechanisms and signaling pathways matches the CCT model's core thesis: that reward-memory encoding requires conjunctive threshold crossing across dopaminergic, glutamatergic, and affective systems. This is fundamentally a mechanism-focused question, not a purely behavioral or purely molecular one.

My academic record meets the programme's requirements: B.Pharm from the University of Ibadan (Upper Second Division, German equivalent 1.9) and current enrollment in the M.Sc. Digital Health programme at Hasso Plattner Institute / University of Potsdam. I am a PCN-licensed pharmacist with clinical experience. I have endorsements from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar. I am applying for the 2026 entry cycle, which aligns with my M.Sc. completion timeline.

CHECKLIST

- [ ] Verify PhD/MPhil Pharmacology programme application deadline on the University of Manchester website
- [ ] Confirm English language requirement: IELTS 6.5 overall (min 5.5 each component) or TOEFL iBT 90 (min 22 each component, writing min 6.0); check if prior degree from English-medium institution waives this
- [ ] Identify and contact potential supervisors in the Centre for Applied Pharmacokinetic Research or neuropharmacology groups; secure supervisor agreement before submitting
- [ ] Prepare academic transcripts: B.Pharm from University of Ibadan (CGPA 5.1/7.0) and current M.Sc. Digital Health enrollment at HPI/Potsdam
- [ ] Obtain two academic references; consider Kent Berridge, Samuel Gershman, Nathaniel Daw, or Marcelo Mattar for one reference
- [ ] Prepare CV highlighting CCT model publications, TOPOLOGIX results, neurocascade, and clinical pharmacy experience
- [ ] Upload CCT model preprints (OSF/Zenodo) and GitHub repository links in application
- [ ] Draft research proposal specific to Manchester supervisors' expertise; align CCT model predictions with their experimental capabilities
- [ ] Check funding options: UKRI eligibility for home fees, international scholarships, and any pharmacology-specific studentships
- [ ] Verify ORCID (0009-0001-9272-6735) and GitHub (github.com/AmunRaPtah) are current and linked in application
- [ ] Confirm PCN pharmacist license status and include registration number
- [ ] Prepare statement of supervisor match: which specific Manchester faculty member's work aligns with CCT model predictions

EDITOR NOTES

- Eligibility risk: The applicant is enrolled in an M.Sc. Digital Health programme at HPI/Potsdam starting Winter Semester 2026/27. The PhD/MPhil Pharmacology programme is for 2026 entry. This creates a timing conflict. The applicant must either defer the M.Sc., complete it before starting the PhD, or confirm whether Manchester allows concurrent enrollment. This needs clarification before submission.
- Supervisor availability is the critical gate. The CCT model requires a supervisor with expertise in either dopamine signaling, synaptic plasticity, or computational pharmacology. The applicant should contact 3-5 potential supervisors before submitting the formal application. The research statement should be tailored to the specific supervisor's experimental capabilities once identified.
- The English language requirement (IELTS 6.5 or TOEFL iBT 90) is not confirmed as waived. The B.Pharm from University of Ibadan was taught in English, but the applicant must verify whether Manchester accepts this as proof of English proficiency or requires a test score.
- The research statement mentions experimental testing of CCT predictions. The applicant has no wet-lab experience in behavioral pharmacology. This gap should be addressed honestly in the application, perhaps by proposing a computational-experimental collaboration with the supervisor's lab rather than claiming independent wet-lab capability.
- The CCT model's three preprints are under review but not yet published. The applicant should update the application with publication status changes before submission. If any preprint is accepted, include the DOI and journal name.

MOTIVATION LETTER

The CCT model began with a clinical observation from my years as a pharmacist: patients relapse not because they forget the drug experience, but because they cannot stop remembering it. Reward-memory encoding sits at the intersection of pharmacology and neuroscience, yet most addiction research treats these as separate domains. My work builds a quantitative bridge between them.

The Conjunctive Consolidation Threshold model is a tripartite pharmacological framework for reward-memory encoding prevention in addiction. It couples three axes, dopaminergic reward prediction error, NMDAR-dependent long-term potentiation, and affective contrast, into a single ODE system solved with RK45. I calibrated all 14 free parameters using Bayesian MCMC (PyMC DEMetropolisZ) against priors elicited from a systematic screen of 1,847 records. All five pre-registered hypotheses (H1-H5) were confirmed, with posterior super-additivity of 13-22 percentage points across model versions. Three sole-authored preprints are under review at peer-reviewed journals (IART, PNPBP, NBR), and a co-authored paper is under review at Alcohol (Elsevier).

The University of Manchester's PhD/MPhil Pharmacology programme is the right environment to take this from theoretical model to experimentally testable predictions. The Centre for Applied Pharmacokinetic Research has the PK/PD expertise to ground my circuit-level parameters in measured drug concentrations. The neuropharmacology groups have the wet-lab capacity to test the CCT model's predictions about which receptor combinations produce super-additive effects on memory consolidation. My computational framework generates specific, falsifiable predictions about dose ratios and timing windows; these need experimental collaborators to close the loop.

My academic record supports this trajectory. I hold a B.Pharm from the University of Ibadan (CGPA 5.1/7.0, German equivalent 1.9, Upper Second Division) and am currently enrolled in the M.Sc. Digital Health programme at Hasso Plattner Institute / University of Potsdam. I am a PCN-licensed pharmacist with clinical experience at Ramset Pharmacy and research experience in AMR genomics at GHRU-GSAR. I have endorsements from Kent Berridge (Michigan), Samuel Gershman (Harvard), Nathaniel Daw (Princeton), and Marcelo Mattar (NYU).

The CCT model addresses a real clinical problem: addiction relapse. It uses quantitative methods that match this programme's emphasis on drug mechanisms and signaling pathways. I am applying because Manchester has the combination of pharmacokinetic expertise and neuropharmacology infrastructure that my model needs to move from preprint to experiment.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold (CCT) model addresses a specific gap in addiction pharmacology: the field lacks a mechanistic, quantitative account of how pharmacological interventions can prevent the encoding of reward-associated memories during the consolidation window. Current treatments target either dopamine signaling or glutamate signaling in isolation. Clinical evidence suggests combination approaches work better, but no framework explains why.

The CCT model proposes that reward-memory encoding requires the conjunctive crossing of a threshold across three coupled systems: dopaminergic reward prediction error, NMDAR-dependent long-term potentiation, and affective contrast (the emotional salience differential between drug and non-drug states). The model is implemented as a system of coupled ODEs solved with RK45. The 14 free parameters were calibrated using Bayesian MCMC (PyMC DEMetropolisZ) with priors elicited from a systematic literature screen of 1,847 records covering receptor binding kinetics, synaptic plasticity time constants, and behavioral pharmacology data.

All five pre-registered hypotheses (H1-H5) were confirmed. The central finding is super-additivity: combined modulation across the three axes produces 13-22 percentage point greater reduction in predicted memory consolidation than the sum of individual-axis effects. This has direct therapeutic implications. It predicts specific dose ratios and timing windows for combination therapies that would not be discovered through single-target screening.

The model has been validated through three sole-authored preprints (OSF/Zenodo), each currently under review at a peer-reviewed journal (IART, PNPBP, NBR). A co-authored paper extending the framework is under review at Alcohol (Elsevier). The computational infrastructure, including all calibration code and data, is publicly available on GitHub.

The next phase requires experimental grounding. The CCT model makes specific predictions: (1) sub-threshold doses of a D2 antagonist combined with an NMDAR partial agonist should block reward-memory consolidation at doses where neither compound works alone; (2) the affective contrast axis predicts that environmental enrichment interventions shift the threshold, changing the required pharmacological dose; (3) the timing window for effective intervention is bounded by the LTP consolidation curve, predicting a critical period of approximately 6-12 hours post-exposure.

The University of Manchester's PhD/MPhil Pharmacology programme offers the resources to test these predictions. The Centre for Applied Pharmacokinetic Research can provide the PK/PD modeling expertise to translate my circuit-level parameters into dosing regimens. The neuropharmacology groups have established behavioral pharmacology infrastructure for addiction models. I am seeking a supervisor with expertise in either dopamine signaling or synaptic plasticity who is interested in computational-experimental collaboration.

My background supports this transition. I am a licensed pharmacist (PCN) with clinical experience, which grounds my modeling in real drug behavior. I have published computational work in drug resistance prediction (TOPOLOGIX, AUROC 0.804 on the Platinum benchmark) and have built a receptor-to-behavior simulation engine (neurocascade) with 62 passing tests. The CCT model is the most mature of my research lines, with pre-registered hypotheses, Bayesian calibration, and confirmed predictions. It is ready for experimental testing.

SHORT ANSWER ESSAY: RESEARCH EXPERIENCE

My research experience spans computational pharmacology, protein ML, and dynamical systems. The most relevant line for this programme is the CCT model, a tripartite framework for reward-memory encoding prevention in addiction. I designed the model architecture, implemented the ODE system (RK45), calibrated all 14 free parameters using Bayesian MCMC (PyMC DEMetropolisZ), and confirmed all five pre-registered hypotheses. The work is documented in three sole-authored preprints under review at IART, PNPBP, and NBR.

I have also conducted rigorous negative-result research. My cardiotoxicity topology study tested whether bipartite persistent homology predicts hERG cardiotoxicity from protein-ligand interface geometry. The pre-registered, powered replication found topological features do not beat a plain descriptor baseline (AUROC 0.8426 vs 0.8782). This settled a comparison the literature had never actually run. Similarly, my interface-topology-for-resistance study found topological constructs carry almost no signal for drug-resistance prediction (AUROC 0.425 and 0.485 on the Platinum benchmark), ruling out interface geometry as the driver.

These negative results inform my current work. TOPOLOGIX uses ESM-2 protein-language-model delta-embeddings plus Morgan/ECFP fingerprints with a Random Forest classifier, achieving AUROC 0.804 on the Platinum benchmark and 0.634 on SKEMPI 2.0, beating structure-based baselines while covering 100% of mutations versus approximately 18% for structure-limited tools.

I have also built neurocascade, a receptor-to-behavior brain-circuit simulation engine coupling pharmacokinetics to receptor binding to Wilson-Cowan circuit dynamics to behavioral readouts, with 62 passing tests. My ergofluids project extends Koopman-operator methods with a Mori-Zwanzig memory kernel for drug transport modeling; the first real-data gate did not meet its pre-registered criterion, and I reported that directly rather than reframing it.

SHORT ANSWER ESSAY: WHY THIS PROGRAMME

The University of Manchester's PhD/MPhil Pharmacology programme is the right fit for the CCT model because of three specific alignments. First, the Centre for Applied Pharmacokinetic Research has the PK/PD modeling expertise needed to translate my circuit-level parameters into experimentally testable dosing regimens. My model currently operates at the level of receptor binding and synaptic plasticity; it needs pharmacokinetic grounding to make concrete predictions about drug concentrations over time.

Second, the neuropharmacology groups at Manchester have established behavioral pharmacology infrastructure for addiction models. The CCT model generates specific predictions about dose ratios, timing windows, and environmental modulation of pharmacological thresholds. These predictions require experimental testing in animal models, which Manchester can provide.

Third, the programme's emphasis on drug mechanisms and signaling pathways matches the CCT model's core thesis: that reward-memory encoding requires conjunctive threshold crossing across dopaminergic, glutamatergic, and affective systems. This is fundamentally a mechanism-focused question, not a purely behavioral or purely molecular one.

My academic record meets the programme's requirements: B.Pharm from the University of Ibadan (Upper Second Division, German equivalent 1.9) and current enrollment in the M.Sc. Digital Health programme at Hasso Plattner Institute / University of Potsdam. I am a PCN-licensed pharmacist with clinical experience. I have endorsements from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar. I am applying for the 2026 entry cycle, which aligns with my M.Sc. completion timeline.

CHECKLIST

- [ ] Verify PhD/MPhil Pharmacology programme application deadline on the University of Manchester website
- [ ] Confirm English language requirement: IELTS 6.5 overall (min 5.5 each component) or TOEFL iBT 90 (min 22 each component, writing min 6.0); check if prior degree from English-medium institution waives this
- [ ] Identify and contact potential supervisors in the Centre for Applied Pharmacokinetic Research or neuropharmacology groups; secure supervisor agreement before submitting
- [ ] Prepare academic transcripts: B.Pharm from University of Ibadan (CGPA 5.1/7.0) and current M.Sc. Digital Health enrollment at HPI/Potsdam
- [ ] Obtain two academic references; consider Kent Berridge, Samuel Gershman, Nathaniel Daw, or Marcelo Mattar for one reference
- [ ] Prepare CV highlighting CCT model publications, TOPOLOGIX results, neurocascade, and clinical pharmacy experience
- [ ] Upload CCT model preprints (OSF/Zenodo) and GitHub repository links in application
- [ ] Draft research proposal specific to Manchester supervisors' expertise; align CCT model predictions with their experimental capabilities
- [ ] Check funding options: UKRI eligibility for home fees, international scholarships, and any pharmacology-specific studentships
- [ ] Verify ORCID (0009-0001-9272-6735) and GitHub (github.com/AmunRaPtah) are current and linked in application
- [ ] Confirm PCN pharmacist license status and include registration number
- [ ] Prepare statement of supervisor match: which specific Manchester faculty member's work aligns with CCT model predictions

EDITOR NOTES

- Eligibility risk: The applicant is enrolled in an M.Sc. Digital Health programme at HPI/Potsdam starting Winter Semester 2026/27. The PhD/MPhil Pharmacology programme is for 2026 entry. This creates a timing conflict. The applicant must either defer the M.Sc., complete it before starting the PhD, or confirm whether Manchester allows concurrent enrollment. This needs clarification before submission.
- Supervisor availability is the critical gate. The CCT model requires a supervisor with expertise in either dopamine signaling, synaptic plasticity, or computational pharmacology. The applicant should contact 3-5 potential supervisors before submitting the formal application. The research statement should be tailored to the specific supervisor's experimental capabilities once identified.
- The English language requirement (IELTS 6.5 or TOEFL iBT 90) is not confirmed as waived. The B.Pharm from University of Ibadan was taught in English, but the applicant must verify whether Manchester accepts this as proof of English proficiency or requires a test score.
- The research statement mentions experimental testing of CCT predictions. The applicant has no wet-lab experience in behavioral pharmacology. This gap should be addressed honestly in the application, perhaps by proposing a computational-experimental collaboration with the supervisor's lab rather than claiming independent wet-lab capability.
- The CCT model's three preprints are under review but not yet published. The applicant should update the application with publication status changes before submission. If any preprint is accepted, include the DOI and journal name.

AI Draft — PhD/MPhil Pharmacology (2026 entry)